Half Yearly Report and Accounts  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Half Yearly Report and Accounts  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Kazia Half Year Accounts and Appx 4D  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Quarterly Activities/Appendix 4C Cash Flow Report  
 
    Appendix 4C - quarterly  
 
    Kazia half year accounts and Appx 4D  
 
    Appendix 4C - quarterly  
 
    Kazia receives $1.02m R&D cash rebate  
 
    Appendix 4C - quarterly  
 
    Kazia Annual Report to shareholders  
 
    Appendix 4C - quarterly  
 
    Kazia Half Year Accounts and Appx 4D  
 
    Kazia receives $1.4m R&D cash rebate  
 
    Kazia Annual Report to shareholders  
 
    Kazia receives $2.2m R&D cash rebate  
 
    Kazia Annual Report to shareholders  
 
    Kazia Appendix 4E and financial report  
 
    Kazia Half Year Accounts and Appx 4D  
 
    Novogen Annual Report to shareholders  
 
    Novogen financial report and Appendix 4E  
 
    Novogen half year accounts and Appx 4D  
 
    Novogen Annual Report to shareholders  
 
    Novogen Receives R&D Tax Incentive Cash Refund of $2.8M  
 
    Half Yearly Report and Accounts